All News

William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how COVID-19 testing developments have opened doors for developments in respiratory syncytial virus (RSV) testing.

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to abstracts presenting findings from the 3-part LIBERTY-EoE-TREET study.

Quality measures are the lifeblood of practice transformation, but learning which ones make a difference—and how to use them to drive change—is as much an art as a science, according to 3 oncology care leaders who discussed the topic Friday at the 2022 Community Oncology Conference, presented by the Community Oncology Alliance.

Low functional status based on Duke Activity Status Instrument score was associated with higher cardiometabolic risk among individuals 45 years and older living with HIV, this new multinational cohort study found.

During a panel at the Community Oncology Alliance’s Community Oncology Conference, speakers discuss practice-level efforts to reduce cancer care disparities.

Across the studies of a new analysis, there was a significant risk difference in motor milestone response and improvement in Hammersmith Infant Neurological Examination score.

FoundationOne CDx has been approved as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 alternations eligible for treatment with EGFR tyrosine kinase inhibitors.

Recent research presented at the 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting examined different aspects of the use of biologics for severe asthma.

As a result of being less likely than men to receive lifesaving treatment when experiencing cardiogenic shock, women were significantly less likely to survive in the short and long term.

Christopher Phillips, MD, a rheumatologist in Kentucky, discusses some of the insurance challenges for patients confronted by prior authorization and the possible impact on their disease and quality of life.

Existing research appears to suggest these patients can be treated similarly to patients with other genetic subtypes of cutaneous melanomas.

Lalan Wilfong, MD, vice president of Payer Relations & Practice Transformation at The US Oncology Network, speaks on how use of health economics and outcomes research has benefitted patient care in the community oncology setting and where it can be further leveraged in the pursuit of value-based care.

Despite current challenges in targeting pancreatic cancer with CAR T-cells, novel targets and strategies hold promise in this difficult disease setting.

Jim Schwartz, RPh, corporate pharmacy manager, Texas Oncology, discussed pharmacy challenges regarding equitable care and distribution of specialty drugs in the community oncology setting.

A recent study found that a nurse practitioner/community health worker intervention was a feasible and acceptable strategy for addressing how social determinants of health (SDOH) and comorbidities influence chronic obstructive pulmonary disease (COPD) self-management.

Addressing avoidable emergency department (ED) utilization takes interventions in partnership with providers.

Public financial statements from 9 dermatology groups backed by private equity (PE) were analyzed by the researchers, who described a significant decrease in debt valuations of these groups both before and during the COVID-19 pandemic.

Incident end-stage kidney disease cases more than doubled among Asian individuals, and prevalent cases more than tripled for Asian, Native Hawaiian or other Pacific Islander, and Hispanic individuals.

Authors outlined advancements in chimeric antigen receptor-modified T (CAR-T) cell therapy for lung cancer, and accompanying challenges.

Sunil Verma, MD, senior vice president and global head of oncology, medical, at AstraZeneca, talks about advancements in standards of care for uncommon cancers, including cholangiocarcinoma.

A recent review examined currently approved treatments and those under investigation for mantle cell lymphoma.

Based on their findings, the investigators argue a need for more inclusive representation of patients with pulmonary arterial hypertension (PAH) across the weight spectrum.

Eosinophilic esophagitis (EoE) is triggered by food and in this interview, Colette Romero, whose son has the disease, discusses the financial implications for families, including equity considerations.

Barbara McAneny, MD, CEO of the New Mexico Cancer Center, who served as president of the American Medical Association (AMA) in 2018, said the AMA has engaged a law firm to take on the issue of curtailing prior authorization, which oncologists say has become worse with increased vertical integration among health plans and pharmacy benefit managers.

A new COVID-19 response coordinator will replace Jeff Zients; cigarette smoking rates were down in 2020; mental health providers offer telehealth services to Ukraine.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Risk stratification is a difficult process for multiple myeloma (MM), and authors concluded that their multi-tiered model may provide a greater risk assessment benefit than standard stratification systems.

This review sought to give more information about the types of treadmill training that might be beneficial for patients with Parkinson disease and other neurological disorders engaged in physical rehabilitation programs.

Cases of Clostridioides difficile (C diff) have increasingly been reported outside of typical settings, and a survey of general practitioners in France found that many cases can be managed without hospitalization.

Ben Jones, vice president, Government Relations & Public Policy, The US Oncology Network, addresses potential reform at the federal and state level that could accelerate the pursuit of value-based care in the community oncology setting.